↓ Skip to main content

Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study

Overview of attention for article published in BMC Cancer, May 2019
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (58th percentile)

Mentioned by

twitter
3 tweeters
peer_reviews
1 peer review site
facebook
1 Facebook page

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
13 Mendeley
Title
Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study
Published in
BMC Cancer, May 2019
DOI 10.1186/s12885-019-5623-3
Pubmed ID
Authors

Henrik Jespersen, Roger Olofsson Bagge, Gustav Ullenhag, Ana Carneiro, Hildur Helgadottir, Ingrid Ljuslinder, Max Levin, Charlotta All-Eriksson, Bengt Andersson, Ulrika Stierner, Lisa M. Nilsson, Jonas A. Nilsson, Lars Ny

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 13 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 4 31%
Researcher 4 31%
Student > Postgraduate 1 8%
Student > Bachelor 1 8%
Unknown 3 23%
Readers by discipline Count As %
Medicine and Dentistry 7 54%
Immunology and Microbiology 1 8%
Engineering 1 8%
Unknown 4 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2019.
All research outputs
#7,120,632
of 14,061,535 outputs
Outputs from BMC Cancer
#1,562
of 5,348 outputs
Outputs of similar age
#107,626
of 261,246 outputs
Outputs of similar age from BMC Cancer
#1
of 1 outputs
Altmetric has tracked 14,061,535 research outputs across all sources so far. This one is in the 49th percentile – i.e., 49% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,348 research outputs from this source. They receive a mean Attention Score of 4.0. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 261,246 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them